Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6039239 | 0.75 | CYP3A4 (0.37) | IDO1CYP19A1CYP11B1CYP11B2LOXL2 | |
| SCHEMBL6841402 | 0.68 | IDO1 (0.49) | IDO1CYP19A1NOTUMCYP11B1CYP11B2 | |
| SCHEMBL9969422 | 0.67 | LMNA (0.58) | CYP19A1NOTUMLMNAMAPTCYP1A2 | |
| SCHEMBL4404602 | 0.66 | IDO1 (0.54) | IDO1CYP19A1CYP11B1CYP11B2LMNA | |
| SCHEMBL11955039 | 0.63 | LOXL2 (0.43) | CYP19A1CYP11B1CYP11B2LOXL2LMNA | |
| SCHEMBL10026851 | 0.62 | ESR1 (0.39) | IDO1CYP3A4 | |
| SCHEMBL2873467 | 0.62 | LOXL2 (0.43) | IDO1CYP19A1CYP11B1CYP11B2LOXL2 | |
| SCHEMBL16923117 | 0.62 | CYP3A4 (0.54) | IDO1CYP19A1NOTUMCYP11B1CYP11B2 | |
| SCHEMBL12976770 | 0.61 | CYP3A4 (0.35) | IDO1CYP19A1CYP11B1CYP11B2LOXL2 | |
| SCHEMBL2877314 | 0.61 | CYP1A2 (0.44) | CYP19A1CYP11B1CYP11B2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014737-A1 | Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | claimed |
| US-20060014737-A1 | Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014737-A1 | Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors | DNPEP, ASPH, APP | IDO1 1940/4885CYP19A1 3203/4885NOTUM 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.